CSF Heme Neutralization After Hemorrhagic Stroke
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for subarachnoid hemorrhage-related secondary brain injury (SAH-SBI) are limited, and there is a lack of reliable biomarkers for predicting and monitoring this condition, leading to high mortality and long-term neurological disabilities.
Innovation Solution
The use of hemopexin (Hx) and haptoglobin (Hp) to form complexes with cell-free heme and haemoglobin in cerebral spinal fluid (CSF) to neutralize their oxidative and inflammatory effects, thereby preventing or treating adverse secondary neurological outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional treatments and monitoring methods are used for SAH-SBI, then current standard care is provided, but diagnostic accuracy is insufficient and reliable biomarkers are lacking
Solution Approach 1:
The patent introduces cell-free heme and hemoglobin as intermediary biomarkers that mediate between the primary injury (subarachnoid hemorrhage) and secondary brain injury outcomes. These intermediaries provide a measurable link that enables accurate diagnosis and monitoring of SAH-SBI, resolving the contradiction between diagnostic accuracy and reliability of biomarkers.
2Reliability
If limited therapeutic options are used for SAH-SBI, then current standard therapy is provided, but treatment effectiveness is insufficient
Solution Approach 1:
The patent extracts and targets the specific harmful components (cell-free heme and hemoglobin) that drive SAH-SBI pathogenesis. By removing these specific harmful factors through targeted therapies, the treatment effectiveness is improved while maintaining adaptability through mechanism-based treatment strategies.
3Object-affected harmful factors
If no targeted therapy for cell-free heme is used, then general care is provided, but oxidative and inflammatory damage continues unchecked
Solution Approach 1:
The patent converts the harmful oxidative and inflammatory effects of cell-free heme into beneficial outcomes by targeting these harmful factors with specific therapies. The harmful heme is neutralized through mechanisms that transform it into harmless or beneficial forms, thereby reducing damage while managing therapeutic complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the incidence of SAH-SBI manifestations such as angiographic vasospasms, delayed cerebral ischemia, and delayed ischemic neurologic deficits by neutralizing cell-free heme and haemoglobin, offering a targeted therapeutic strategy with diagnostic accuracy exceeding traditional biomarkers.
Implementation Method 1
exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme
Implementation Method 2
exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, cell-free Hb
Implementation Method 3
Hx can reduce or otherwise prevent cell-free heme-mediated adverse secondary neurological outcomes (e.g., oxidative tissue damage, neuroinflammation)
Data Source
AI summary
The present disclosure relates generally to methods of treating or preventing an adverse secondary neurological outcome in a subject following a haemorrhagic stroke accompanied by extravascular erythrolysis and release of cell-free heme and/or cell-free haemoglobin (Hb) into a cerebral spinal fluid (CSF), the method comprising exposing the CSF of a subject in need thereof to a therapeutically effective amount of hemopexin (Hx) and for a period of time sufficient to allow the Hx to form a complex with, and thereby neutralise, the cell-free heme and, optionally, exposing the CSF of the subject to a therapeutically effective amount of haptoglobin (Hp) and for a period of time sufficient to allow the Hp to form a complex with, and thereby neutralise, the cell-free Hb.